Strumento inattivo

Azioni Cubist Pharmaceuticals Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	13/01/15
Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen	21/12/14
Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées	20/12/14
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	20/12/14
Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	10/12/14

Dirigenti	Titolo	Età	Da
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/97

Amministratori	Titolo	Età	Da
Martin Hermanus Soeters BRD	Director/Board Member	70	01/09/06
Kenneth J. Martin BRD	Director/Board Member	70	25/09/13

Settore

	Variaz. 1 gen.	Capi.
CSL LIMITED	-4,66%	86,13 Mrd
SAMSUNG BIOLOGICS CO.,LTD.	+1,32%	39,82 Mrd
BIOGEN INC.	-19,27%	30,42 Mrd
UCB	+57,86%	25,23 Mrd
BIOMARIN PHARMACEUTICAL INC.	-16,09%	15,35 Mrd
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,14%	11,95 Mrd
INCYTE CORPORATION	-17,69%	11,6 Mrd
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,00%	11,51 Mrd
SWEDISH ORPHAN BIOVITRUM AB	+5,24%	8,71 Mrd